BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1034 related articles for article (PubMed ID: 36581948)

  • 1. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
    Wang Z; Liu H; Gong Y; Cheng Y
    Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer.
    Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J
    Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
    Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
    Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and validation of an aging-related gene signature for prognosis prediction of patients with breast cancer.
    Li J; Qi C; Li Q; Liu F
    Cancer Rep (Hoboken); 2023 Mar; 6(3):e1741. PubMed ID: 36323529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
    Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unfolded protein response signature unveils novel insights into breast cancer prognosis and tumor microenvironment.
    Zhou N; Kong D; Lin Q; Yang X; Zhou D; Lou L; Huang F
    Cancer Genet; 2023 Aug; 276-277():17-29. PubMed ID: 37343507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer.
    Liu Z; Ren C; Cai J; Yin B; Yuan J; Ding R; Ming W; Sun Y; Li Y
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and development of an independent immune-related genes prognostic model for breast cancer.
    Chen L; Dong Y; Pan Y; Zhang Y; Liu P; Wang J; Chen C; Lu J; Yu Y; Deng R
    BMC Cancer; 2021 Mar; 21(1):329. PubMed ID: 33785008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis on tumor immune microenvironment and construction of a prognosis model for immune-related skin cutaneous melanoma.
    Wu M; Wang Z; Zhang J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):671-681. PubMed ID: 37539569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature.
    Shen L; Huang H; Li J; Chen W; Yao Y; Hu J; Zhou J; Huang F; Ni C
    Front Immunol; 2023; 14():1199465. PubMed ID: 37469520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel prognostic signature based on single-cell combined bulk RNA analysis in breast cancer.
    Xiao Y; Hu G; Xie N; Yin L; Pan Y; Liu C; Lou S; Zhu C
    J Gene Med; 2024 Feb; 26(2):e3673. PubMed ID: 38404059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pyroptosis-related gene signature predicting survival and tumor immune microenvironment in breast cancer and validation.
    Gong M; Liu X; Zhao X; Wang H
    BMC Cancer; 2022 Sep; 22(1):1005. PubMed ID: 36138348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
    Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
    Front Oncol; 2022; 12():915662. PubMed ID: 36033441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer.
    Cui H; Ren X; Dai L; Chang L; Liu D; Zhai Z; Kang H; Ma X
    Front Immunol; 2023; 14():1145552. PubMed ID: 36969219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
    Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M
    Front Immunol; 2023; 14():1198826. PubMed ID: 38035071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.